Skip to Content

The Cooper Companies Inc COO

Rating as of

Morningstar’s Analysis

Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Cooper Sees Normality on Horizon, Near-Term Outlook Bolstered by MiSight and Paragard; Maintain FVE

Aaron Degagne Equity Analyst

Analyst Note

| Aaron Degagne |

Narrow-moat Cooper Companies reported fiscal first-quarter revenue of $680.5 million, an increase of 3% on a constant-currency basis. These results were about in line with our expectations given the prepandemic comparable of the year-ago period, and we are maintaining our $315 fair value estimate. With shares trading above $370, we think the stock remains moderately overpriced.

Read Full Analysis

Company Profile

Business Description

Cooper Companies operates two units: CooperVision and CooperSurgical. Accounting for approximately 75% of total sales, CooperVision is the the second- largest player in the oligopolistic contact lens market. Over 50% of CooperVision's sales are in international territories. The second unit, CooperSurgical, develops and manufactures diagnostic and surgical products for gynecologists and obstetricians, including the Paragard IUD, which Cooper acquired from Teva in 2017.

6101 Bollinger Canyon Road, Suite 500
San Ramon, CA, 94583
T +1 925 460-3600
Sector Healthcare
Industry Medical Instruments & Supplies
Most Recent Earnings Oct 31, 2020
Fiscal Year End Oct 31, 2021
Stock Type Slow Growth
Employees 12,000